Generic drug makers get to keep 180-day exclusivity when the FDA de-lists patents.
|
Drug maker hit hard in Q3 as rival launches generic blood thinner.
|
Generics companies scramble as Merck’s cholesterol-lowering statin loses its patent.
|
Growth is shifting, but the industry is none the poorer for that.
|
The U.S. Federal Trade Commission will investigate whether authorized generics flout competition laws.
|
The Indian pharmaceutical giant buys Romanian and Belgian generic drug companies.
|
Drug giants draw opposite reactions to their fourth-quarter earnings.
|
The two drug makers settle a patent dispute over a sleep drug, sending Cephalon’s shares up 5 percent.
|
Indian pharma giant plans trial on Pfizer’s blood-pressure drug patent.
|
The United Kingdom’s High Court rules in favor of the world’s largest pharmaceutical company on the main Lipitor patent.
|
“Me-too” drugs are sapping too much from national health budgets, according to Canadian scientists.
|
As the Swiss giant aims for more power in the vaccine market, Chiron’s shares jump more than 18 percent.
|
Teva Pharmaceutical acquiring generic pharmaceutical maker IVAX, rendering Teva the largest generic drug maker.
|
Brand-name drug prices rise; a black box for seven anti-psychotics; Pfizer under fire; Medtronic gets an OK.
|
Indian pharmaceutical company Dr. Reddy’s announces a $56-million partnership with the country’s largest private equity investor.
|
Microscience gains funding; Heart devices get European boost; India moves closer to product patents; Gilead and Japan Tobacco strike a deal; VISX gets FDA approval.
|
India’s government proposes western-style patent laws to make it illegal to copy drugs protected by intellectual property laws elsewhere.
|